The supplemental application for BB-1701 for injection from Bliss Biopharmaceuticals (Hangzhou) has been accepted by NMPA

CAR-T Digest - August 2020

04 February 2026: The supplemental application for BB-1701 for injection from Bliss Biopharmaceuticals (Hangzhou) has been accepted by NMPA

The latest update from China’s drug regulatory system shows progress in application processing, with a supplemental application for BB-1701 for injection officially accepted for review
According to data released by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the application was formally undertaken on February 4, 2026, confirming its entry into the regulatory review workflow
The filing was submitted by Bliss Biopharmaceutical and has been assigned the acceptance number CXSB2600026, which serves as the official regulatory tracking identifier
BB-1701 for injection is classified as a therapeutic biological product, with the submission categorized as a supplementary application under Registration Category 1, reflecting its placement within China’s innovative biologics framework
With the application now accepted by the CDE, BB-1701 formally advances into the next stage of regulatory processing, marking a procedural milestone for Bailisco Biopharmaceutical within China’s biologics review system